The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Feasibility of treatment with bispecifics in patients with myeloma with prior BCMA exposure
Bhagirathbhai Dholaria, MBBS, Vanderbilt University Medical Center, Nashville, TN, comments on sequencing bispecific antibodies and CAR-T therapy in patients with multiple myeloma with prior exposure to BCMA-targeted therapies. While there is limited data on this topic, data from the TRIMM-2 trial (NCT0410819) indicates that more than half of the patients that had been treated with BCMA-directed bispecific antibodies or CAR-T therapies had a response to talquetamab + daratumumab. However, it is important to determine whether this response is durable and to examine the overall efficacy and safety of this strategy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
